论文部分内容阅读
目的：观察醒脑静注射液联合依达拉奉治疗急性脑出血的临床疗效。方法：88例急性脑出血患者随机分为观察组和对照组各44例。两组均给予常规基础治疗,在此基础上,对照组予依达拉奉注射剂30 mg+0.9%氯化钠注射液500 ml,ivd (30 min内滴完),bid；观察组在对照组基础上再加用醒脑静注射液10 ml+5.0%葡萄糖注射液250 ml,ivd,qd。治疗4周后观察两组患者治疗前后NIHSS评分、格拉斯哥昏迷( GCS)评分,脑水肿和脑血肿体积,高敏C反应蛋白( hs-CRP)、白细胞介素-6(IL-6)水平等指标变化,记录两组药品不良反应发生情况。结果：治疗后,两组患者GCS评分均明显提高(P<0.05),NIHSS评分明显下降(P<0.05),且观察组优于对照组(P<0.05)。治疗后两组患者脑水肿和脑血肿体积明显缩小(P0.05)。两组治疗后hs-CRP、IL-6水平均有明显下降(P<0.05),且观察组下降较对照组更明显(P0.05)。结论：醒脑静注射液联合依达拉奉治疗急性脑出血效果较单用拉达拉奉更为理想。“,”Objective:To observe the effect of Xingnaojing injections combined with edaravone in the treatment of acute cerebral hemorrhage. Methods:The patients with acute cerebral hemorrhage were randomly divided into the observation group and the control group with 44 cases in each. The two groups were both given conventional treatment. The control group was treated with 30mg edara-vone injections in 0. 9% 500ml sodium chloride infusions, ivd (infused in 30min), bid, while the observation group was additionally given 10ml Xingnaojing injections in 5. 0% 250ml glucose infusions, ivd, qd. After the 4-week treatment, NIHSS score, GCS score, brain edema and hematoma volume, the levels of high sensitive C reactive protein (hs-CRP) and interleukin-6 (IL-6) before and after the treatment in the two groups were observed and compared, and adverse drug reactions were also recorded. Results: After the treat-ment, GCS score was significantly improved (P<0. 05) and NIHSS score was decreased significantly (P<0. 05) in the two groups, and the observation group was better than the control group (P<0. 05). After the treatment, cerebral edema and hematoma volume was notable reduced in the two groups (P0. 05). The levels of hs-CRP and IL-6 were decreased significantly after the treatment in the two groups (P<0. 05), and the decrease in the observation group was more significant than that in the control group (P0. 05). Conclusion: Compared with edaravone alone, Xingnaojing injections combined with edaravone in the treatment of acute cerebral hemorrhage show more significant efficacy.